Crossject | ALCJ FP | Supergenerics | France | Updates

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Things get going

Target

Upside 201%

Price (€) 3.85

Target Price (€) 11.6

Market Cap (€M) 141

Perf. 1W:	1.58%
Perf. 1M:	-13.3%
Perf. 3M:	-0.26%
Perf Ytd:	16.8%

10 day relative perf. to stoxx600:	0.90%
20 day relative perf. to stoxx600:	-6.44%

EPS change22/05/2020

Download

No major changes after the release of the FY19 report
Change in EPS	2019 : € -0.49 vs -0.48	ns
	2020 : € -0.32 vs -0.34	ns
No major changes to our forecasts. The only ones come from the integration of the detailed FY19 numbers which marginally impact our forecasts, with hardly any change to our target price.

22 May 20 EPS change
No major changes after the release of the FY19...

29 Mar 20 Earnings/sales releases
Meaningless FY19 results and product update

23 Dec 19 Financing issue
Extra-financing to increase visibility

20 Nov 19 Financing issue
A €2.6m non-dilutive issue

15 Oct 19 Latest
Cooperation agreement with the US Departmen...

10 Sep 19 Earnings/sales releases
H1 19: no surprise

10 Jul 19 Financing issue
Warrants to existing shareholders

19 Jun 19 Latest
A commercial success

18 Apr 19 EPS change
The 2018 bonds fully converted

18 Mar 19 EPS change
No major change post FY18 results